ADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update
ADMA BIOLOGICS, INC. (ADMA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update 2Q 2026 Total Revenue of $124.4 Million, Increasing 2% Year-over-Year 2Q 2026 ASCENIV Revenue of $102.9 Million, Increasing 24% Year-over-Year BIVIGAM Utilization Stabilized wit
How this was made
The 30-second read
Why it matters
The filing updates quarterly performance and reiterates FY2026 revenue and profitability ranges, with management attributing growth to accelerating ASCENIV demand, improving utilization, and expanding real-world evidence.
Market read
Traders can reprice ADMA expectations using the reiterated FY2026 guidance ranges and the quarter’s execution narrative around ASCENIV utilization and demand.
What to watch
Real-world evidence is supportive but not the same as controlled clinical endpoints; investors may discount the magnitude of utilization-driven revenue until longer-term persistence is demonstrated.
Background
This is an SEC Form 8-K with Exhibit 99.1 reporting ADMA’s second quarter 2026 financial results and business update for its immune globulin products, especially ASCENIV.
Ticker impact
ADMA reported 2Q 2026 results and reiterated FY2026 guidance, citing ASCENIV demand acceleration and real-world evidence supporting growth.
Likely positive bias for ADMA shares into the next few sessions, with volatility around how credible the utilization acceleration and margin outlook appear versus expectations.
The filing provides fresh quarterly datapoints (revenue, GAAP/adjusted earnings, utilization commentary) and explicit FY2026 ranges, which are actionable for positioning and expectation-setting.
Market effects
Reinforces demand and payer-access narrative for immune globulin therapies, potentially supporting sentiment across specialty biopharma with similar commercial models.
Limited direct regional spillover; primarily U.S. commercial execution and payer coverage signals.
Low, as the disclosure is focused on U.S. immune globulin market dynamics and company-specific real-world evidence.
Counterpoint
The company reiterates guidance while acknowledging ongoing U.S. immune globulin pricing pressure, so upside may be capped if utilization gains do not translate into durable revenue and margin expansion.
Key entities
- companyADMA Biologics, Inc.
U.S.-based commercial biopharmaceutical company reporting 2Q 2026 results and reiterating FY2026 guidance.
- productASCENIV
ADMA’s immune globulin product highlighted as the principal growth driver, with utilization acceleration and real-world outcomes data.
- productBIVIGAM
Immune globulin product discussed as having stabilized demand with sequential improvement in utilization and revenue.
- eventACAAI Annual Scientific Meeting (Nov 2026)
Conference where ADMA submitted an abstract on real-world ASCENIV-treated patient outcomes.
